References
- Mandell LA, Bartlett JG, Dowell SF, File TM Jr., Musher DM, Whitney C. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 2003; 37: 1405-33.
- Schito GC, Varaldo PE, Nicoletti G. Activity of levofloxacin on respiratory pathogens: results of the SEMPRE Italian Study (2000-2002). ICAAC, Chicago, 2003.
- Bartlett JG, Breiman RF, Mandell LA, File TM Jr. Community-acquired pneumonia in adults: guidelines for management. Infectious Diseases Society of America. Clin Infect Dis 1998; 26: 811-38.
- Mandell LA, Marrie TJ, Grossman RF, Chow AW, Hyland RH. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian Community-Acquired Pneumonia Working Group. Clin Infect Dis 2000; 31: 383-421.
- Halm EA, Teirstei AS. Management of community-acquired pneumonia. N Engl J Med 2002; 347: 2039-45.
- Metlay JP, Fine MJ. Testing strategies in the initial management of patients with community-acquired pneumonia. Ann Intern Med 2003; 138: 109-18.
- Bonfiglio G. Is levofloxacin as active as ciprofloxacin against Pseudomonas aeruginosa? Chemotherapy 2001; 47: 239-242.
- Santini L et al. Attività in vitro della levofloxacina nei confronti dei patogeni Gram-negativi nosocomiali. Congresso Nazionale SIC 2001, Firenze 2-5 Dicembre, Abstr A14.
- Gesu GP et al. Attività in vitro di levofloxacina e ciprofloxacina su 1361 ceppi batterici da campioni clinici: studio multicentrico con E-test. Congresso IBAT 2001, Abstr p. 178.
- Piccoli L et al. Susceptibility of bacterial respiratory pathogens collected in Italy in 1998-1999 to levofloxacin (LVX) and ciprofloxacin (CIP). Nosocomial Infection Today – 3rd International Symposium. Venezia, Novembre 2000. GIMMOC 2000;4:14
- Isenberg HD, Alperstein P, France K. In vitro activity of ciprofloxacin, levofloxacin, and trovafloxacin, alone and in combination with beta-lactams, against clinical isolates of Pseudomonas aeruginosa, Stenotrophomonas maltophilia, and Burkholderia cepacia. Diagn Microbiol Infect Dis 1999;33(2):81-86
- Visalli MA, Jacobs MR, Appelbaum PC. Determination of activities of levofloxacin, alone and combined with gentamicin, ceftazidime, cefpirome, and meropenem, against 124 strains of Pseudomonas aeruginosa by checkerboard and time-kill methodology. Antimicrob Agents Chemother 1998; 42, 4: 953-55.
- Gesu GP, Marchetti F, Piccoli L, Cavallero A. Levofloxacin and ciprofloxacin in vitro activities against 4,003 clinical bacterial isolates collected in 24 Italian laboratories. Antimicrob Agents Chemother 2003; 47, 2: 816-19.
- Bonfiglio G, Cascone C, Azzarelli C et al. Levofloxacin in vitro activity and time-kill evaluation of Stenotrophomonas maltophilia clinical isolates. J Antimicrob Chemother 2000; 45(1): 115-117.